Your browser doesn't support javascript.
loading
A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non-small-cell lung cancer.
Camidge, D Ross; Berge, Eamon M; Doebele, Robert C; Ballas, Marc S; Jahan, Thierry; Haigentz, Missak; Hoffman, David; Spicer, James; West, Howard; Lee, Pablo; Yang, Ling; Joshi, Adarsh; Gao, Ling; Yurasov, Sergey; Mita, Alain.
Afiliação
  • Camidge DR; *University of Colorado Anschutz Medical Campus, Aurora, CO; †New York University School of Medicine, New York, NY; ‡University of California San Francisco, San Francisco, CA; §Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY; ‖Tower Hematology Oncology Medical Group, Beverly Hills, CA; ¶King's College London, Guy's Hospital, London, United Kingdom; #Swedish Cancer Institute, Seattle, WA; **ImClone Systems, a Wholly-owned Subsidiary of Eli Lilly and Company, Bridgewater,
J Thorac Oncol ; 9(10): 1532-9, 2014 Oct.
Article em En | MEDLINE | ID: mdl-25170639
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2014 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2014 Tipo de documento: Article